Orchestra BioMed Holdings (OBIO) EBIT Margin (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly EBIT Margin of 20069.09% for Q1 2026, down 1788925.0% year-over-year from N/an in Q1 2025, and down 91967.94% quarter-over-quarter from 21.85% in Q4 2025.
Orchestra BioMed Holdings (OBIO) EBIT Margin (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported EBIT Margin for 5 consecutive years, with 20069.09% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT Margin fell 1788925.0% year-over-year to 20069.09%; the TTM figure through Mar 2026 stood at 167.96% (up 221593.0% YoY), while the FY2025 annual figure was 154.73%, up 228276.0% from the prior year.
- EBIT Margin retreated to 20069.09% in Q1 2026 per OBIO's latest filing, from 21.85% in the prior quarter.
- Across five years, EBIT Margin topped out at 21.85% in Q4 2025 and bottomed at 20069.09% in Q1 2026.
- Historically, EBIT Margin has averaged 3207.6% across 5 years, with a median of 2166.97% in 2024.
- Annual changes were most pronounced in 2025 — EBIT Margin jumped 661355 bps — and 2026, when it slumped 1788925 bps.
- Orchestra BioMed Holdings' EBIT Margin stood at 891.02% in 2022, then plunged by 435 bps to 4763.74% in 2023, then tumbled by 38 bps to 6591.7% in 2024, then surged by 100 bps to 21.85% in 2025, then plunged by 91968 bps to 20069.09% in 2026.
- Business Quant data shows OBIO's EBIT Margin at 20069.09% in Q1 2026, 21.85% in Q4 2025, and 2359.23% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Orchestra BioMed Holdings | 265.06 Mn | 80.63 Mn | 63,000.00 | -25,404.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25,404.55% |
| Mar 31, 2026 | -20,069.09% |
| Dec 31, 2025 | 21.85% |
| Sep 30, 2025 | -2,359.23% |
| Jun 30, 2025 | -2,311.84% |
| Mar 31, 2025 | -2,179.84% |
| Dec 31, 2024 | -6,591.70% |
| Sep 30, 2024 | -1,655.72% |
| Jun 30, 2024 | -2,166.97% |
| Mar 31, 2024 | -2,326.29% |
| Dec 31, 2023 | -4,763.74% |
| Sep 30, 2023 | -3,466.35% |
| Jun 30, 2023 | -1,415.96% |
| Mar 31, 2023 | -991.84% |
| Dec 31, 2022 | -891.02% |
| Sep 30, 2022 | -865.61% |
| Jun 30, 2022 | -1,903.74% |
| Mar 31, 2022 | -592.15% |